Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy

S. Sinha; M. Lacy; J. Mikhael; S. Hayman; F. Buadi; K. Detweiler-Short; A. Dispenzieri; M. Gertz; D. Dingli; S. V. Rajkumar; S. K. Kumar

doi:10.1038/leu.2011.279

Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy

S. Sinha, M. Lacy, J. Mikhael, S. Hayman, F. Buadi, K. Detweiler-Short, A. Dispenzieri, M. Gertz, D. Dingli, S. V. Rajkumar, S. K. Kumar

Research output: Contribution to journal › Letter › peer-review

10 Scopus citations

Original language	English (US)
Pages (from-to)	839-841
Number of pages	3
Journal	Leukemia
Volume	26
Issue number	4
DOIs	https://doi.org/10.1038/leu.2011.279
State	Published - Apr 2012

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/leu.2011.279

Cite this

@article{520651be8c0a47f5bccbfbc6ee2090db,

title = "Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy",

author = "S. Sinha and M. Lacy and J. Mikhael and S. Hayman and F. Buadi and K. Detweiler-Short and A. Dispenzieri and M. Gertz and D. Dingli and Rajkumar, {S. V.} and Kumar, {S. K.}",

note = "Funding Information: MQL has received research funding from Celgene; JM has receivedresearch funding from Celgene, Onyx, Novartis; AD has received research funding from Celgene and Travel award binding site; MAG has received Honoraria from Celgene, Millenium, Neotope Eisai, Inc., Lilly Research Laboratories, Optum Health Education, Research to Practice, Physician{\textquoteright}s Education Resource and Amgen, Inc.; and SKK has received research funding from Celegene, Genzyme, Millenium, Novartis, Bayer, Merck and Cephalon, and has participated in Advisory board for Genzyme. The remaining authors declare no conflict of interest. Funding Information: This study was supported in part by the Paul Calabresi Award for Clinical Oncology, CA90628 (SKK) and the Hematologic Malignancies Program (Mayo Clinic).",

year = "2012",

month = apr,

doi = "10.1038/leu.2011.279",

language = "English (US)",

volume = "26",

pages = "839--841",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy

AU - Sinha, S.

AU - Lacy, M.

AU - Mikhael, J.

AU - Hayman, S.

AU - Buadi, F.

AU - Detweiler-Short, K.

AU - Dispenzieri, A.

AU - Gertz, M.

AU - Dingli, D.

AU - Rajkumar, S. V.

AU - Kumar, S. K.

N1 - Funding Information: MQL has received research funding from Celgene; JM has receivedresearch funding from Celgene, Onyx, Novartis; AD has received research funding from Celgene and Travel award binding site; MAG has received Honoraria from Celgene, Millenium, Neotope Eisai, Inc., Lilly Research Laboratories, Optum Health Education, Research to Practice, Physician’s Education Resource and Amgen, Inc.; and SKK has received research funding from Celegene, Genzyme, Millenium, Novartis, Bayer, Merck and Cephalon, and has participated in Advisory board for Genzyme. The remaining authors declare no conflict of interest. Funding Information: This study was supported in part by the Paul Calabresi Award for Clinical Oncology, CA90628 (SKK) and the Hematologic Malignancies Program (Mayo Clinic).

PY - 2012/4

Y1 - 2012/4

UR - http://www.scopus.com/inward/record.url?scp=84859646589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859646589&partnerID=8YFLogxK

U2 - 10.1038/leu.2011.279

DO - 10.1038/leu.2011.279

M3 - Letter

C2 - 21986842

AN - SCOPUS:84859646589

SN - 0887-6924

VL - 26

SP - 839

EP - 841

JO - Leukemia

JF - Leukemia

IS - 4

ER -

Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this